Strs Ohio Purchases 8,700 Shares of Progyny, Inc. (NASDAQ:PGNY)

Strs Ohio raised its stake in Progyny, Inc. (NASDAQ:PGNY) by 85.3% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 18,900 shares of the company’s stock after acquiring an additional 8,700 shares during the period. Strs Ohio’s holdings in Progyny were worth $702,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. RiverPark Advisors LLC increased its holdings in Progyny by 54.0% in the 4th quarter. RiverPark Advisors LLC now owns 1,067 shares of the company’s stock valued at $40,000 after acquiring an additional 374 shares during the last quarter. Acadian Asset Management LLC bought a new stake in Progyny in the 3rd quarter valued at $53,000. CWM LLC increased its holdings in Progyny by 16.1% in the 3rd quarter. CWM LLC now owns 3,490 shares of the company’s stock valued at $119,000 after acquiring an additional 483 shares during the last quarter. Duality Advisers LP bought a new stake in Progyny in the 3rd quarter valued at $202,000. Finally, Olympiad Research LP bought a new stake in Progyny in the 3rd quarter valued at $222,000. 94.93% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on PGNY. Cantor Fitzgerald reiterated an “overweight” rating and issued a $48.00 price target on shares of Progyny in a report on Wednesday, February 28th. Barclays began coverage on shares of Progyny in a research note on Wednesday, January 3rd. They issued an “overweight” rating and a $48.00 price objective for the company. Truist Financial reissued a “buy” rating and issued a $46.00 price objective on shares of Progyny in a research note on Wednesday, April 17th. KeyCorp dropped their price objective on shares of Progyny from $45.00 to $43.00 and set an “overweight” rating for the company in a research note on Wednesday, February 28th. Finally, SVB Leerink began coverage on shares of Progyny in a research note on Monday, February 26th. They issued an “outperform” rating and a $49.00 price objective for the company. Ten investment analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $48.30.

Progyny Trading Down 0.3 %

PGNY stock opened at $32.50 on Friday. Progyny, Inc. has a 12 month low of $29.44 and a 12 month high of $44.95. The company has a 50-day moving average price of $36.02 and a 200 day moving average price of $35.63. The stock has a market cap of $3.12 billion, a PE ratio of 52.42, a P/E/G ratio of 1.34 and a beta of 1.48.

Progyny (NASDAQ:PGNY) last released its quarterly earnings results on Tuesday, February 27th. The company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of $0.09 by $0.04. Progyny had a net margin of 5.70% and a return on equity of 12.64%. The firm had revenue of $269.94 million during the quarter, compared to analysts’ expectations of $274.08 million. During the same period in the previous year, the company earned $0.03 EPS. The firm’s revenue for the quarter was up 26.0% compared to the same quarter last year. Sell-side analysts forecast that Progyny, Inc. will post 0.7 EPS for the current year.

Insider Buying and Selling

In other Progyny news, Chairman David J. Schlanger sold 1,000 shares of the business’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $37.52, for a total value of $37,520.00. Following the completion of the sale, the chairman now directly owns 83,631 shares of the company’s stock, valued at approximately $3,137,835.12. The transaction was disclosed in a filing with the SEC, which is available through this link. In other Progyny news, CFO Mark S. Livingston sold 11,165 shares of the business’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $37.62, for a total value of $420,027.30. Following the completion of the sale, the chief financial officer now directly owns 50,119 shares of the company’s stock, valued at approximately $1,885,476.78. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Chairman David J. Schlanger sold 1,000 shares of the business’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $37.52, for a total transaction of $37,520.00. Following the completion of the sale, the chairman now directly owns 83,631 shares of the company’s stock, valued at $3,137,835.12. The disclosure for this sale can be found here. In the last ninety days, insiders sold 120,515 shares of company stock valued at $4,570,131. Company insiders own 12.30% of the company’s stock.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.